Table 1.
Distribution of soluble immune checkpoint-related proteins in control, AIS and IAC patients.
| Control (N=35) | AIS (N=43) | IAC (N=81) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Early stage (N=50) | Late stage (N=31) | ||||||||
| Marker | Median (IQR) pg/ml | Median (IQR) pg/ml | Median (IQR) pg/ml | Median (IQR) pg/ml | *P | **P | ***P | ****P | †P trend |
| sBTLA | 280.52 (113.59-511.51) | 228.01 (181.84-274.19) | 211.52 (170.17-290.44) | 244.28 (178.41-329.29) | 0.68 | 0.55 | 0.98 | 0.25 | 0.98 |
| sCD27 | 556.25 (466.54-681.61) | 489.69 (399.67-629.86) | 735.4 (476.1-1198.23) | 1382.75 (943.44-1745.74) | 2.24E-01 | 5.37E-05 | 1.05E-06 | 2.93E-04 | 7.80E-09 |
| sCD28 | 64.51 (21.04-161.75) | 31.77 (22.24-44.18) | 29.67 (23.31-38.53) | 49.74 (32.81-71.38) | 0.19 | 0.29 | 0.73 | 0.14 | 0.84 |
| sCD80 | 106.43 (67.27-137.99) | 66.42 (43.94-91.73) | 109.73 (67.42-341.77) | 285.04 (90.3-398.26) | 1.46E-02 | 9.74E-02 | 4.44E-05 | 0.03 | 5.00E-04 |
| sCD137 | 177.01 (149.97-257.58) | 65.11 (46.03-111.6) | 132.06 (79.18-188.46) | 176.76 (130.55-216.77) | 2.85E-05 | 4.59E-02 | 2.30E-05 | 0.02 | 0.19 |
| sCTLA4 | 7.81 (6.74-20.85) | 5.19 (2.46-6.83) | 5.91 (3.89-9.37) | 9.63 (5.35-10.64) | 0.03 | 0.30 | 0.14 | 0.25 | 0.93 |
| sGITR | 37.98 (16.02-68.48) | 18.1 (9.7-71.37) | 10.64 (6.92-26.63) | 10.64 (6.85-17.99) | 0.87 | 0.08 | 0.16 | 0.67 | 0.04 |
| sHVEM | 13.86 (8.98-22.35) | 4.87 (2.59-17.23) | 20.08 (14.71-29.34) | 22.51 (16.71-41.88) | 0.08 | 0.01 | 0.02 | 0.6 | 0.01 |
| sIDO | 6.68 (4.52-10.7) | 5.89 (4.15-8.21) | 6.88 (4.15-12.42) | 8.96 (3.62-14.79) | 0.37 | 0.76 | 0.2 | 0.64 | 0.51 |
| sLAG3 | 12.97 (9.93-16.02) | 15.09 (15.09-15.09) | 14.63 (9.31-20.24) | 10.66 (6.4-17.47) | 1.00 | 0.93 | – | 0.33 | 0.37 |
| sPD1 | 13.78 (9.35-24) | 12.39 (7.2-16.06) | 16.16 (11.23-22.43) | 17.05 (12.01-20.95) | 0.36 | 0.64 | 0.01 | 0.46 | 0.08 |
| sPDL1 | 0.35 (0.32-0.45) | 0.29 (0.24-0.37) | 0.18 (0.11-0.29) | 0.24 (0.13-0.29) | 3.82E-03 | 3.63E-05 | 0.05 | 0.87 | 3.88E-05 |
| sPDL2 | 268.82 (218.56-339.59) | 321.21 (228.13-402.55) | 467.19 (349.75-694.05) | 702.54 (388.59-852.24) | 0.21 | 3.65E-08 | 1.16E-06 | 0.07 | 1.99E-10 |
| sTIM3 | 131.31 (113.25-155.83) | 28.98 (17.84-56.54) | 39.49 (16.45-66.41) | 67.75 (28.78-156.22) | 2.347E-03 | 0.04 | 0.33 | 0.11 | 0.96 |
AIS, adenocarcinoma in situ; IAC, invasive adenocarcinoma. Early stage indicates stage I&II disease, Late stage indicate stage III&IV disease, the staging criteria according to NCCN Clinical Practice Guidelines Non-small cell lung cancer v1, 2022 *P indicates Control vs. AIS, **P indicates Control vs. IAC, ***P indicates AIS vs. IAC, ****P indicates early stage vs. late stage, †P for trend was analyzed using Jonckheere-Terpstra test.